See Stories from Region:
Filter by Date:
  • close  
  • close  

Prestium Pharma, Inc. Announces Plans for Release of Improved OLUX® (Clobetasol Propionate) Foam

Prestium Pharma, Inc. announced it is planning to launch an improved version of OLUX® (clobetasol propionate), 0.05% Foam.

(Business Wire Prestium Pharma, Inc. announced it is planning to launch an improved version of OLUX® (clobetasol propionate), 0.05% Foam. The new product is designed to improve overall performance and patient compliance and includes modifications allowing for greater product uniformity, the ability to apply the foam directly to the affected area, and a valve assembly that does not require inversion for application. Earlier this year, a patent application was filed relating to the new product.

“The improvements in this new version of OLUX® will enhance an already great product,” said John Denman, general manager of Prestium. “OLUX® is used by thousands of patients in the U.S., and we look forward to formally introducing the key qualities of the product to physicians and patients in the second half of 2015.”

OLUX® Foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older. OLUX® Foam is for topical use and not for oral, ophthalmic, or intravaginal use. OLUX® Foam can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during treatment or after withdrawal of treatment. Risk factors include the use of high potency topical corticosteroid, use over a large surface area or to areas under occlusion, prolonged use, altered skin barrier, liver failure, and use in pediatric patients. In clinical trials, the most common adverse events associated with the use of OLUX® Foam were burning, dryness, and other reactions at the application site. Treatment beyond 2 consecutive weeks is not recommended, and total dosage should not exceed 50 grams per week. Learn more about OLUX® and see Full Prescribing Information by visiting

About Prestium Pharma
Prestium Pharma, Inc. is subsidiary of Renaissance Acquisition Holdings LLC and is focused on marketing high quality pharmaceutical brands in the United States. More information on Prestium can be found at